In recent 20 years, with the rapid development of molecular biology, people have studied the etiology, genetics, epidemiology, immunology, pathogenesis, pathophysiology, diagnostic methods, prevention, anti-asthma drug pharmacology, development of new anti-asthma drugs, inhalation methods, physical therapy, psychotherapy, quality of life, asthma education, the relationship between asthma and allergic rhinitis, specific asthma, asthma and computer management of asthmatic animals. According to the current research, it can be considered that the basic pathological changes of any severity and type of asthma are airway inflammatory changes, and this non-specific airway inflammation is the key factor leading to airway hyperresponsiveness, airway ventilation disorder, clinical symptoms and chronic asthma in asthma patients. The concept of airway inflammation is of great significance in guiding the diagnosis, prevention and treatment of asthma (especially the development of new anti-inflammatory and anti-asthma drugs and long-acting β2 receptor agonists) and basic research, and many new academic viewpoints have been put forward. At present, the 17 global asthma conference has been held, which makes the research and prevention of asthma large-scale and standardized. The international medical community has developed the research of asthma into an independent medical system, which is called asthma. As an asthmatic, he should have rich knowledge in allergy, pediatrics, otolaryngology, dermatology, psychopsychology, environmental medicine and rehabilitation.

The pathological changes of asthma are mainly airway eosinophil infiltration, supplemented by chronic airway inflammation with mast cells, lymphocytes and macrophages infiltration. The main clinical features are airway hyperresponsiveness and airway ventilation disorder induced by airway inflammation. Therefore, in the past 20 years, attempts have been made to use acute bronchiectasis therapy to replace the treatment principle of chronic anti-inflammatory therapy in the past, and great success has been achieved. The clinical symptoms of asthma can be effectively controlled by inhibiting airway inflammation. However, the epidemiological investigation in recent 20 years has not found that the incidence and mortality of asthma have decreased, suggesting that although anti-inflammatory therapy including inhaled corticosteroids is the main method of asthma at present, its long-term curative effect and the prediction of asthma improvement are not optimistic, and there is obviously a lack of effective treatment methods to reduce the incidence and mortality of asthma and improve the prognosis of asthma. With the continuous development of molecular biotechnology, it is found that a large number of cytokines (mainly interleukin), various immunocompetent cells or inflammatory cells, and various inflammatory mediators in body fluids participate in the regulation of the pathogenesis of asthma in different forms, which makes us pay attention to studying and clarifying the pathogenesis of asthma from a systematic perspective. But so far, most of the research is still limited to local airway inflammation, and there are few studies on the systemic pathogenesis of asthma, so there are few systematic treatments for asthma. Modern research has recognized that atopy is the most important factor that makes people susceptible to asthma. Therefore, from the current research on asthma, it is obviously inappropriate to focus on local anti-inflammatory treatment. We should start with gene therapy and immunomodulation therapy to prevent and treat atopy. Xolair developed in recent years is a successful drug. Looking forward to the future, because the incidence of asthma is increasing year by year, the reason is still unclear. In the future, we should strengthen the basic research of asthma and develop new treatment methods to reduce the incidence of asthma. In the short term, in the future clinical research of asthma, anti-inflammatory drugs with less side effects and stronger effects should be further developed. In the long run, the current research focus on airway local inflammation should gradually shift to the study of systemic immunology, pathophysiology, genetics and immunopharmacology of asthma patients, and adjust the genetic abnormalities and immune function defects of asthma patients from the perspective of medical genetics and medical immunology, especially by regulating and treating various cytokines in the cytokine network that cause airway hyperresponsiveness, which may be the main research direction of asthma treatment in 2 1 century. China should carry out research on prevention and treatment of asthma with China characteristics according to the national conditions, such as treating asthma with traditional Chinese medicine and integrated traditional Chinese and western medicine, and extracting effective components from single traditional Chinese medicine or prescription.

1998, Professor Li Minghua and Professor Yin Kaisheng, more than 20 colleagues in the United Nations who are committed to the prevention and treatment of asthma, compiled and published Asthma with more than 900,000 words. The content is comprehensive and novel, closely combined with domestic clinical practice, and printed several times after publication. Reprinted in 2006,170,000 words, printed five times in succession. It has been welcomed by clinicians.

For more than 20 years, the research on asthma at home and abroad is in the ascendant and very active. Various types and scales of academic seminars have been held at home and abroad, tens of thousands of scientific research papers have been published, various related monographs have been edited and published, and various new theories and viewpoints have been put forward from time to time, all of which show that the research work of asthma prevention and treatment is full of vitality. In this situation, both the author and the reader hope that Asthma can be republished with a new look as soon as possible, reflecting the new progress of asthma research and asthma prevention and treatment in recent five years in time, and further promoting the development of asthma prevention and treatment in China. It is in this situation that scholars such as Li Minghua and Yin Kaisheng revised and supplemented the first edition, and completed the compilation and publication of the second edition of Asthma. Asthma Second Edition * * *1.2000 words, divided into 7 1 chapters. Compared with the first edition, all chapters in the second edition of Asthma have been updated and added. The most prominent change is that the second edition of Asthma has added many new contents. Including clinical pharmacology, immunopharmacology, traditional Chinese medicine immunopharmacology, the relationship between respiratory tract infection and asthma and its treatment ideas, clinical thinking of asthma diagnosis and treatment, combined treatment of asthma, surgery and anesthesia of asthma patients, quality of life evaluation of asthma patients, application of evidence-based medicine in asthma prevention and treatment, and asthma socio-economics. In addition, the development and clinical trials of antiasthmatic drugs are systematically introduced, and the development and research of antiasthmatic drugs in 2 1 century are prospected. Therefore, we have reason to believe that the second edition of this book will be of great help to the prevention and treatment of asthma in China.

In the past two years, we all feel that although the research on asthma has been going on, various new drugs have been on the market and new papers have been published, the treatment principles and ideas of asthma have not changed much, and the whole prevention and treatment work is in a state of wandering, with few breakthroughs, and it seems to have entered a platform period. The majority of asthma patients are eager to cure asthma, but the various treatment methods we use at present can only control asthma at best, which forms a strong contrast, which is undoubtedly an invisible pressure for all our colleagues who are committed to asthma prevention and treatment, and it is also the driving force for us to forge ahead. At the same time, we must think and answer a very important question, where is the cure of asthma, and how to make breakthroughs and innovations in asthma research as soon as possible?